# RAD BioMed

RAD BioMed is a Private Equity based in Tel Aviv, Israel.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Tel Aviv, Israel
- **Region:** Middle East
- **Address:** Tel Aviv, Israel
- **Founded:** 1992
- **Assets under management:** Undisclosed
- **Website:** radbiomed.com
- **LinkedIn:** https://www.linkedin.com/company/rad-biomed-accelerator

## Regulatory record

- **Reports private funds:** No

## About

RAD BioMed is an early-stage investment firm co-founded to bring the RAD Bynet Group's entrepreneurial spirit and company-building expertise into the healthcare space. Its mission is to strengthen Israel's MedTech industry through hands-on investment. The firm focuses on MedTech, Health, Technology, and Energy sectors.

## Sectors

- MedTech
- Health
- Technology
- Energy

## People

- Yehuda Zisapel — Co-Founder
- Prof. Nava Zisapel — Co-Founder and Chairperson
- Carmi Zisapel — Business Development Manager
- Kobi Elad — Legal Counsel

## Questions

### Does RAD BioMed invest in companies beyond MedTech?

Yes. While MedTech remains the core, the firm's website now lists Health, Technology, and Energy as target sectors. Recent portfolio additions include in-wheel suspension technology for e-mobility and a partnership with Square One Labs to build companies in energy and physical AI. This marks a deliberate expansion from RAD BioMed’s original healthcare-only mandate.

### Is RAD BioMed a venture capital fund or a corporate venture arm?

RAD BioMed functions more like an accelerator and investment arm than a traditional VC fund. It is wholly part of the RAD Bynet Group and provides in-house legal, business development, and operational support to its portfolio companies. The firm does not appear to raise external LP capital, reinforcing its structure as a strategic company builder rather than a pooled investment vehicle.

### Who is Prof. Nava Zisapel and how does she influence the portfolio?

Prof. Nava Zisapel is co-founder and chairperson of RAD BioMed, a full professor of neuro-biochemistry at Tel Aviv University, and founder of CNS drug developer Neurim Pharmaceuticals. Her scientific background directly shapes the firm's diligence on medical-device and life-science deals, with a particular focus on neurological and ophthalmic applications evident in the portfolio.

### What stage does RAD BioMed typically enter a company?

The firm enters at the very earliest stages — seed and start-up — often providing the first institutional capital and operational scaffolding. RAD BioMed's model is designed to take a company from concept through to commercial launch, with exits like Vectorious (acquired by Edwards) and Belkin Vision (acquired by Alcon) illustrating a path from incubation to strategic acquisition.

### How does RAD BioMed relate to the broader RAD Bynet Group?

RAD BioMed is a direct subsidiary and the designated healthcare investment arm. It shares back-office, legal, and strategic resources with sibling companies that have collectively achieved 9 IPOs and 10 M&A exits. This linkage allows portfolio companies to access RAD Bynet's IT, cybersecurity, and infrastructure expertise, creating a cross-pollination effect uncommon in standalone MedTech incubators.

## Related profiles

- [Radazon Capital](https://altss.com/profile/radazon-capital)
- [Radcliff Management](https://altss.com/profile/radcliff-management)

---

Last updated: 2026-07-10T10:47:06.000Z

Canonical page: https://altss.com/profile/rad-biomed

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology